{"product_id":"avanos-marketing-mix","title":"Avanos Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e4Ps Strategy Framework - Actionable in Minutes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSee how Avanos aligns product positioning, pricing logic, distribution channels, and promotional tactics to drive clinical adoption and commercial performance. This snapshot surfaces strategic strengths and gaps; the full 4Ps Marketing Mix Analysis delivers an editable, presentation-ready deep dive with supporting data, category examples, and prioritized, actionable recommendations to accelerate decisions. Continue through the page to review the complete, brand-specific framework and templates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigestive Health Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos leads the enteral feeding market with MIC-KEY gastrostomy tubes and accessories, holding about 32% global market share in 2025 and generating roughly $420M in annual revenue from digestive health solutions.\u003c\/p\u003e\n\u003cp\u003eThe products deliver reliable nutrition and medication for patients with compromised digestion, focusing on safety and comfort through soft retention balloons and low-profile designs favored by clinicians and caregivers.\u003c\/p\u003e\n\u003cp\u003eIn late 2025 Avanos rolled out enhanced connector designs that cut misconnections by an estimated 68% in trials and reduced average administration time by 22%, improving ease of use in hospitals and home care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcute Pain Management Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe ON-Q elastomeric pump remains a cornerstone of Avanos acute pain systems, delivering targeted non-opioid local anesthetics at steady rates; hospitals report up to 30% reduction in opioid use and a 0.8-day shorter LOS (length of stay) after implementation (2024 real-world registries).\u003c\/p\u003e\n\u003cp\u003eRecent iterations boost flow-rate accuracy to ±5% and cut filling time by ~40%, enabling 25% faster turnover in high-volume ORs and supporting Avanos's acute pain revenue, which was $220M in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterventional Pain Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCOOLIEF Cooled Radiofrequency sits as Avanos' premium interventional pain offering, targeting chronic knee, hip, and shoulder pain with minimally invasive, water-cooled lesions that are larger and longer-lasting than standard RF; it aims to reduce surgical rates-studies show up to 60% pain reduction at 12 months.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRespiratory Health Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos Respiratory Health Devices include closed suction catheters and oral care kits that reduce ventilator-associated pneumonia (VAP) risk; VAP affects ~10-20% of ventilated patients and adds ~$40,000 per case to hospital costs (US data, 2024).\u003c\/p\u003e\n\u003cp\u003eThese devices are critical in ICUs where infection rates drive reimbursements and safety scores; Avanos updates products with antimicrobial materials and ergonomic designs to cut nursing time and contamination.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eClosed suction + oral care = VAP risk reduction\u003c\/li\u003e\n\u003cli\u003eVAP incidence ~10-20% of ventilated patients\u003c\/li\u003e\n\u003cli\u003eAvg excess cost per VAP ~ $40,000 (US, 2024)\u003c\/li\u003e\n\u003cli\u003eDesign updates: antimicrobial materials, ergonomic handles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePost-Acute and Home Care Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos bundles medical-grade enteral feeding and wound-care supplies into Post-Acute and Home Care Kits to meet the shift toward home recovery, launched across key US channels in 2024 when 35% of post-acute care shifted home, per CMS trends.\u003c\/p\u003e\n\u003cp\u003eKits aim to cut readmissions by standardizing care-studies show consistent home protocols can reduce readmission 10-20%-and target revenue growth in Avanos's disposables segment, which was $550M in 2024.\u003c\/p\u003e\n\u003cp\u003eFocus is on patient empowerment, caregiver ease, and continuity of care to sustain outcomes and lower total cost of care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBundles: enteral + wound supplies\u003c\/li\u003e\n\u003cli\u003eReadmission reduction: 10-20%\u003c\/li\u003e\n\u003cli\u003eMarket fit: 35% post-acute to home (2024)\u003c\/li\u003e\n\u003cli\u003eSegment revenue: $550M (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos drives growth with MIC-KEY, ON-Q and post-acute disposables boosting safety and home recovery\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos' product portfolio-MIC-KEY enteral systems (32% share, ~$420M 2025), ON-Q pumps ($220M 2024), COOLIEF interventional devices, respiratory\/ICU kits, and Post-Acute home bundles (disposables $550M 2024)-focuses on safety, reduced administration time, lower VAP\/readmission rates, and home recovery to drive disposables and device revenue growth.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003cth\u003eRevenue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMIC-KEY\u003c\/td\u003e\n\u003ctd\u003e32% global share\u003c\/td\u003e\n\u003ctd\u003e$420M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eON-Q\u003c\/td\u003e\n\u003ctd\u003e±5% flow; 30% less opioids\u003c\/td\u003e\n\u003ctd\u003e$220M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDisposables kits\u003c\/td\u003e\n\u003ctd\u003e35% post-acute→home\u003c\/td\u003e\n\u003ctd\u003e$550M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a company-specific deep dive into Avanos's Product, Price, Place, and Promotion strategies, grounded in actual brand practices and competitive context for actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Avanos' 4P marketing strategy into a concise, leadership-friendly snapshot that quickly communicates product, price, place, and promotion decisions to speed stakeholder alignment and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIn North America and Western Europe Avanos uses a specialized direct sales force to manage complex clinical relationships, with ~60% of its commercial reps focused on interventional pain and digestive health as of FY2024 (Avanos FY2024 Form 10-K). \u003c\/p\u003e\n\u003cp\u003eThese reps provide technical expertise and bedside support for advanced procedures, driving procedure adoption-clinical support visits rose ~12% year-over-year in 2024 per company disclosures.\u003c\/p\u003e\n\u003cp\u003eThe direct model helps Avanos navigate value-based purchasing committees at large health systems, supporting contract wins that contributed to a 7% revenue growth in 2024 versus 2023.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distributor Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos maintains a global footprint by using an extensive network of third-party distributors in emerging markets and regions without a direct presence, covering over 80 countries as of Q4 2025 and supplying ~35% of international revenue. Partners are chosen for local regulatory know-how and logistics capacity, reducing stockouts to under 3% annually in pilot markets. This dual-channel model lets Avanos scale faster while keeping international SG\u0026amp;A growth below 5% year-over-year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGroup Purchasing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpa significant volume of avanos healthcare avns sales-about hospital channel revenue in through contracts with group purchasing organizations and integrated delivery networks so securing national gpo positions is essential for access to roughly us hospitals. prioritizes these high-level negotiations keep its wound-care respiratory products as the standard care across massive supporting million net revenue.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmbulatory Surgery Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpas surgical procedures shift to outpatient settings avanos has retooled distribution serve ambulatory surgery centers which now perform about of select in the us as offers smaller-pack skus and tighter delivery windows match asc needs.\u003e\n\u003cpthese centers need compact storage and just-in-time supply avanos reports asc channel growth contributing roughly of its revenue mix in reflecting the sector cost-driven migration from hospitals.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003e57% of select procedures now in ASCs (2024)\u003c\/li\u003e\n\u003cli\u003eAvanos ASC-driven revenue ~18% (2024)\u003c\/li\u003e\n\u003cli\u003eSmaller SKUs, more frequent JIT deliveries\u003c\/li\u003e\n\n\u003c\/pthese\u003e\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrated E-commerce Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvanos integrated with major B2B healthcare e-procurement platforms (e.g., GHX, Premier) to enable automated replenishment and electronic ordering for high-turnover consumables like feeding tubes and catheters.\u003c\/p\u003e\n\u003cp\u003eBy Q4 2025 roughly 58% of routine orders moved to these digital channels, reducing order-processing costs ~22% and freeing sales reps to focus on clinical consultation and value-selling.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e58% routine orders via e-channels by late 2025\u003c\/li\u003e\n\u003cli\u003e22% lower order-processing cost\u003c\/li\u003e\n\u003cli\u003eAutomated inventory cuts stockouts 35%\u003c\/li\u003e\n\u003cli\u003eSales time reallocated to clinical support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos: Direct-rep-led US growth, 80+ country reach, 58% e-orders, 18% ASC revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos uses direct sales in NA\/EU (60% reps in interventional pain\/digestive, FY2024) plus distributors in 80+ countries (35% international revenue, Q4 2025); GPO\/IDN contracts drive ~60% hospital-channel revenue and access to 75% of US hospitals; ASCs now ~57% of select procedures, contributing ~18% revenue (2024); e-procurement handled ~58% orders by Q4 2025, cutting order costs ~22%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect-rep focus\u003c\/td\u003e\n\u003ctd\u003e60% (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries covered\u003c\/td\u003e\n\u003ctd\u003e80+ (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eASC revenue\u003c\/td\u003e\n\u003ctd\u003e18% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eE-orders\u003c\/td\u003e\n\u003ctd\u003e58% (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eAvanos 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Avanos 4P's Marketing Mix document you'll receive instantly after purchase-no surprises. It's the full, ready-made analysis covering Product, Price, Place, and Promotion, delivered in the exact format displayed. This is not a sample or demo; the editable, high-quality file is available for immediate download upon checkout. Buy with confidence-what you see is what you get.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eromotion\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Evidence and Research Publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos centers promotion on robust clinical evidence: since 2020 it funded 45 independent studies and 12 real-world evidence trials showing average device-related infection reduction of 28%, published in peer-reviewed journals like NEJM and JAMA; these publications underpin all marketing collateral and supported a 2024 sales uplift of 9% and a 6-point increase in hospital adoption rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos Academy and Medical Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos Academy uses education as promotion, delivering hands-on workshops, webinars, and certification courses on interventional pain and digestive health products; in 2024 the company reported training over 8,000 clinicians globally, improving correct device usage rates by an estimated 22%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProfessional Medical Congresses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cpavanos keeps a high-profile presence at major medical congresses like the american society of anesthesiologists and key gastroenterology meetings reaching clinicians annually through these forums serve to launch innovations shape practice via opinion leaders. interactive booths live demos let test device features directly supporting year-over-year adoption lift observed after launches in such events cost but drive disproportionate influence on purchasing committees clinical guidelines.\u003e\n\u003c\/pavanos\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeted Digital and Social Media Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos runs targeted digital campaigns on platforms like Doximity and Medscape, using clinical case videos and procedural content to reach anesthesiology, pain-management, and OR teams; in 2024 these channels drove a 28% higher engagement versus broad healthcare ads.\u003c\/p\u003e\n\u003cp\u003eCampaigns emphasize non-opioid pain alternatives with peer-reviewed updates and case studies, improving HCP (healthcare professional) recall by 22% and shortening decision timelines in procurement by an average 14 days.\u003c\/p\u003e\n\u003cp\u003eThe company uses behavioral and workflow signals to time outreach-email opens, EMR-triggered alerts, and portal visits-raising conversion of targeted clinicians to demos by 18% while reducing CPM by 12% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlatforms: Doximity, Medscape, specialty portals\u003c\/li\u003e\n\u003cli\u003eContent: case videos, clinical updates, procedural demos\u003c\/li\u003e\n\u003cli\u003eImpact: +28% engagement, +22% recall, +18% demo conversions\u003c\/li\u003e\n\u003cli\u003eEfficiency: -12% CPM, -14 days to decision\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Awareness Campaigns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAvanos runs disease-state awareness campaigns, partnering with patient advocacy groups to educate on alternatives for chronic pain and digestive issues and to drive patient-initiated demand for technologies like COOLIEF; a 2024 survey found 38% of chronic pain patients asked clinicians about non-opioid options after awareness outreach.\u003c\/p\u003e\n\u003cp\u003eCampaigns stress quality-of-life gains and opioid-avoidance, citing studies showing COOLIEF can reduce pain scores by ~50% at 12 months and cut opioid use in responders by over 30%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners: patient advocacy groups\u003c\/li\u003e\n\u003cli\u003eKey message: opioid avoidance, QoL gains\u003c\/li\u003e\n\u003cli\u003eImpact: 38% ask clinicians post-outreach (2024)\u003c\/li\u003e\n\u003cli\u003eClinical data: ~50% pain reduction at 12 months\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Promotion-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos 2024: Evidence‑led campaign drives +9% sales, +28% digital engagement, 38% patient inquiries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos promotion leverages clinical evidence, education, congress presence, targeted digital campaigns, and patient outreach; 2024 KPIs: 45 studies since 2020, 8,000 clinicians trained, +9% sales, +6 pp hospital adoption, +28% digital engagement, +22% recall, +18% demo conversion, -12% CPM, 38% patient-initiated inquiries.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStudies funded since 2020\u003c\/td\u003e\n\u003ctd\u003e45\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians trained\u003c\/td\u003e\n\u003ctd\u003e8,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales uplift\u003c\/td\u003e\n\u003ctd\u003e+9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital adoption\u003c\/td\u003e\n\u003ctd\u003e+6 pp\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital engagement lift\u003c\/td\u003e\n\u003ctd\u003e+28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCP recall\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDemo conversion\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCPM change\u003c\/td\u003e\n\u003ctd\u003e-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient inquiries post-campaign\u003c\/td\u003e\n\u003ctd\u003e38%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003erice\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eValue-Based Pricing Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos uses value-based pricing that ties product price to measured economic benefit, citing studies showing device-linked 0.8-1.5 day reductions in hospital stay and 20-40% cuts in device-related infection rates, which can lower per-patient costs by $3,000-$10,000 annually (2024 payer analyses).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTiered Contractual Pricing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAvanos uses tiered contractual pricing to serve small clinics and large hospital systems, offering volume discounts and performance-based rebates-contracts with major GPOs can cut prices by 10-25% for commitments above $5m annually (2024 data).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePremium Positioning for Patented Innovations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos prices the patented COOLIEF system at a premium to reflect exclusivity and recoup R\u0026amp;D-Avanos reported R\u0026amp;D spend of $99.7M in FY2024, so higher margins support innovation.\u003c\/p\u003e\n\u003cp\u003eClinical scarcity drives willingness to pay: COOLIEF faces few direct competitors in cooled radiofrequency ablation, and payer reimbursement rates averaged 8-12% above standard interventional codes in 2023, sustaining the premium.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBundled Product Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAvanos uses bundled product agreements offering tiered discounts when hospitals buy across categories (eg, digestive and respiratory), raising average order value and share of wallet; in 2024 Avanos reported 6-9% revenue uplift from cross-category contracts in key accounts.\u003c\/p\u003e\n\u003cp\u003eBundles simplify procurement and cut costs for facilities-clients reported average savings of ~8% per contract and 12% faster order cycles-strengthening long-term partnerships and renewal rates.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTiered discounts boost AOV 6-9%\u003c\/li\u003e\n\u003cli\u003eClient savings ~8% per contract\u003c\/li\u003e\n\u003cli\u003eOrder cycles 12% faster\u003c\/li\u003e\n\u003cli\u003eImproves retention and wallet share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeographic Pricing Adjustments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpavanos adjusts prices by market to match local reimbursement and budgets targeting higher pricing in oecd markets discounts emerging protect volume international sales were of revenue so this matters for margin recovery.\u003e\n\u003cpprice changes reflect gdp per capita payer mix and competitor presence-typical adjustments range by region this keeps products affordable in low-income systems while preserving asps selling prices the us eu.\u003e\n\u003cpthis approach helped sustain global revenue: avanos reported international revenue in fy2024 up vs prior year despite pricing pressure apac.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInternational sales 42% of revenue (FY2024)\u003c\/li\u003e\n\u003cli\u003eRegional price gaps typically 10-30%\u003c\/li\u003e\n\u003cli\u003eInternational revenue $1.12B in FY2024\u003c\/li\u003e\n\u003cli\u003eAdjustments driven by GDP, payer budgets, local competitors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pprice\u003e\u003c\/pavanos\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Price-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAvanos: $99.7M R\u0026amp;D fuels COOLIEF premiuming, 8-12% payer uplift, 6-9% AOV gain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAvanos uses value-based and tiered contractual pricing, with COOLIEF premiuming supported by $99.7M R\u0026amp;D (FY2024) and payer reimbursements 8-12% above interventional codes; volume\/GPO discounts of 10-25% on \u0026gt;$5M deals lift AOV 6-9% and drove 6-9% cross-category revenue uplift in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$99.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl revenue\u003c\/td\u003e\n\u003ctd\u003e$1.12B (42% total)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer premium\u003c\/td\u003e\n\u003ctd\u003e+8-12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGPO discounts\u003c\/td\u003e\n\u003ctd\u003e10-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAOV uplift\u003c\/td\u003e\n\u003ctd\u003e6-9%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Porter's Five Forces","offers":[{"title":"Default Title","offer_id":55640066359369,"sku":"avanos-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0978\/1261\/1145\/files\/avanos-marketing-mix.webp?v=1776708377","url":"https:\/\/five-forces.com\/products\/avanos-marketing-mix","provider":"Porter’s Five Forces","version":"1.0","type":"link"}